Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Completed · Phase 1
Conditions studied: Multiple Myeloma, Blood and Marrow Transplant (BMT)
In brief
This is a phase 1 dose escalation study evaluating the use of activated T-cells to treat relapsed malignancy (cancer) following allogeneic hematopoietic cell transplantation, without causing GvHD.
Key facts
- Study ID
- NCT00185757
- Run by
- Stanford University
- People needed
- 21
- Starts
- 2004-06-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.